Oneness Biotech Co., Ltd.

Fespixon^® Cream

Taiwan FDA Approval number:060827
Package Insert: Download Here (English Version)
FESPIXON^®Cream Clinical Information:
－NCT04962139 (click here for the ongoing phase 3 clinical trail)
－NCT01898923 (click here for the compelete phase 3 clinical trail)
Research Publication/ Abstract: Click Here

▌You are encouraged to report negative side effects of prescription drugs to:
Phone: 0800-215-988
Mail: medicalscience@onenessbio.com.tw

Residents in the United States may join the Phase 3 clinical trial or apply for the use of Fespixon (ON101) via the licensed physician under the Expanded Access Program. For more information, please visit NCT04962139 on clinicaltrials.gov or the EAP page.